Showing results (681-690 of 764) with videos related to
Sort By:
Pageof 77
ESMO Open|August 5, 2025
Health-related quality of life and performance status with NALIRIFOX versus nab-paclitaxel + gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarcinoma: results from the NAPOLI 3 trialD Melisi, T Macarulla, C De La Fouchardière, et al.Journal of the American Heart Association|February 19, 2016
Ndufc2 Gene Inhibition Is Associated With Mitochondrial Dysfunction and Increased Stroke Susceptibility in an Animal Model of Complex Human DiseaseSperanza Rubattu, Sara Di Castro, Herbert Schulz, et al.ESMO Open|February 13, 2026
NALIRIFOX versus nab-paclitaxel and gemcitabine in older patients with treatment-naive metastatic pancreatic cancer: a subgroup analysis of the pivotal NAPOLI 3 trialT Macarulla, R Pazo Cid, M S Womack, et al.Scientific Reports|March 27, 2020
In-depth characterization of a novel live-attenuated Mayaro virus vaccine candidate using an immunocompetent mouse model of Mayaro diseaseMânlio Tasso de Oliveira Mota, Vivian Vasconcelos Costa, Michelle Amantéa Sugimoto, et al.Nature Genetics|February 16, 2005
Integrated transcriptional profiling and linkage analysis for identification of genes underlying diseaseNorbert Hubner, Caroline A Wallace, Heike Zimdahl, et al.Lancet (London, England)|September 14, 2023
NALIRIFOX versus nab-paclitaxel and gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarcinoma (NAPOLI 3): a randomised, open-label, phase 3 trialZev A Wainberg, Davide Melisi, Teresa Macarulla, et al.Frontiers in Endocrinology|June 24, 2021
The Impact of 68Gallium DOTA PET/CT in Managing Patients With Sporadic and Familial Pancreatic Neuroendocrine TumoursDaniel J Cuthbertson, Jorge Barriuso, Angela Lamarca, et al.Cell Stem Cell|April 7, 2009
A genome-scale RNAi screen for Oct4 modulators defines a role of the Paf1 complex for embryonic stem cell identityLi Ding, Maciej Paszkowski-Rogacz, Anja Nitzsche, et al.The Lancet. Oncology|June 22, 2014
Gefitinib for oesophageal cancer progressing after chemotherapy (COG): a phase 3, multicentre, double-blind, placebo-controlled randomised trialSusan J Dutton, David R Ferry, Jane M Blazeby, et al.Molecular Cell|September 23, 2022
SAMHD1 controls innate immunity by regulating condensation of immunogenic self RNAShovamayee Maharana, Stefanie Kretschmer, Susan Hunger, et al.Pageof 77